Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Down 7.1% in September

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 1,040,000 shares, a decline of 7.1% from the September 15th total of 1,120,000 shares. Currently, 3.4% of the company’s shares are sold short. Based on an average daily trading volume, of 184,400 shares, the short-interest ratio is currently 5.6 days.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new position in Werewolf Therapeutics in the first quarter valued at about $10,922,000. Millennium Management LLC grew its position in shares of Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after buying an additional 544,881 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 26.8% in the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after buying an additional 233,909 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Werewolf Therapeutics by 410.5% during the 2nd quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after acquiring an additional 107,900 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Werewolf Therapeutics by 119.8% during the first quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock valued at $1,119,000 after acquiring an additional 94,212 shares during the last quarter. 64.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

HOWL has been the topic of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd.

Werewolf Therapeutics Stock Up 2.5 %

Shares of Werewolf Therapeutics stock opened at $2.06 on Thursday. Werewolf Therapeutics has a 1 year low of $1.57 and a 1 year high of $8.19. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.13 and a quick ratio of 12.13. The stock has a market cap of $89.52 million, a price-to-earnings ratio of -1.89 and a beta of 0.45. The firm’s 50-day moving average is $2.10 and its two-hundred day moving average is $3.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $2.00 million. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 48.25%. As a group, research analysts expect that Werewolf Therapeutics will post -1.64 earnings per share for the current fiscal year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.